Brought to you by 
Amgen grants NantPharma license to Phase II gastric cancer compound
14 Jan 2021
Executive Summary
Amgen Inc. licensed NantWorks LLC's NantPharma LLC subsidiary exclusive global rights (excluding Japan, Russia, and certain central Asian countries) to develop and commercialize the c-met tyrosine kinase inhibitor AMG337, currently in Phase II for gastric and esophageal cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen grants NantPharma license to Phase II gastric cancer compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice